SwedenSweden

Medivir Selects Drug Candidate and Wins EU Patent

08.05.2004

Huddinge - Swedish Medivir AB and Peptimmune Inc., Cambridge (USA), have jointly selected an orally active, small molecule inhibitor of the protease enzyme Cathepsin S as a candidate drug (see EuroBiotechNews 4/04). The Cathepsin S programme is a joint-venture between the two companies with a strong research and intellectual property position in the autoimmune and inflammatory disease areas. The programme includes a license to the intellectual property rights to Cathepsin S as a therapeutic target from the Massachusetts Institute of Technology and issued and pending patents in the United States, Europe and rest of world.
Cathepsin S plays a significant role in the activation of immune responses. Potential clinical applications of the inhibitors include controlling the initiation or progression of immune system disorders such as multiple sclerosis, rheumatoid arthritis, allergic asthma or pain. The project now enters the pre-clinical development with the aim to file an Investigational New Drug application (IND) and to enter clinical phase I trials.
Also in late March the European Patent Office has granted a patent on Medivir AB's herpes project ME-609. The company currently has operational responsibility for development of the project and preparations towards phase III studies are ongoing. Parallel to this, Medivir is seeking a partnership or joint venture for this advanced project. The patent (EP0909498B1) that has been granted in all the EU-15 countries, Switzerland and the new EU member states Slovenia, Liechtenstein, Latvia and Lithuania, extends to 2016. It covers all topical pharmaceuticals that include the antiviral acyclovir and the glucocorticoid hydrocortisone and also claims the use of such products in the treatment of herpes infections.

SwedenSweden

17.11.2011

Exton/Helsingborg – A Swedish specialist for improving glucocorticoid replacement therapy has attracted transatlantic attention. DuoCort Pharma AB, based in Helsingborg, was bought by ViroPharma Incorporated, an US-based...

SwedenSweden

01.10.2011

Uppsala/Basel – Swedish life science initiative Uppsala BIO is set to team up with drugmaker Hoffman-La Roche AG. For the next three years, the cluster will become the ninth member – and the first from Europe – of the Swiss...

SwedenSweden

01.10.2011

Uppsala – Backed by strong clinical research, the development of Orexo AB’s drug candidate OX219 for treatment of opioid dependence is gathering momentum. A clinical Phase I study was carried out to decide the commercial...

SwedenSweden

20.08.2011

Petach Tikva/Lund – Active Biotech AB suffered a severe setback in the development of its oral multiple sclerosis drug laquinimod. Together with ally Teva (Israel), the Swedish drugmaker announced that the substance failed in...

SwedenSweden

08.08.2011

Lund - Researchers from Lund University may have found a viable alternative to animal testing. In an article in the open access journal BMC Genomics (August 2011) they demonstrated that the response of laboratory grown human...

SwedenSweden

04.08.2011

Uppsala - After good interim results Oasmia wastes no time and starts the approval process for its ovarian cancer drug Paclical. The interim analysis, based on data from approximately 400 patients, showed the expected efficacy of...

SwedenSweden

02.08.2011

Petach Tikva/Lund - Active Biotech's experimental multiple sclerosis drug laquinimod failed in a phase III-trial. This is a major setback for the Swedish drug maker and its ally Teva Pharmaceutical Industries from Israel. Both...

SwedenSweden

30.06.2011

Huddinge, Sweden - Medivir cashes in on Medivir. For EUR 31m the Swedishspecialty pharma company sold all North American remaining rights forXerese, a drug against cold sores (herpes labialis), to Swedish Meda. InFebruary 2010,...

SwedenSweden

15.06.2011

Uppsala/Tokyo – Orexo AB’s cancer pain treatment Abstral has reached the Canadian drug market. The Swedish drugmaker confirmed yesterday that Paladin Labs Inc have launched marketing of the sublingual formulation of fentanyl in...

SwedenSweden

12.06.2011

Stockholm – Swedish investor Karolinska Development AB outperformed its own expectations in its Initial Public Offering on the Nasdaq OMX Stockholm. The company sold 15.2 million shares at SEK40 during the offering, raising a...

Displaying results 11 to 20 out of 182

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/1/article/medivir-selects-drug-candidate-and-wins-eu-patent.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF64.2%
  • EPIGENOMICS3.37 EUR6.0%
  • BB BIOTECH141.00 EUR5.9%

FLOP

  • WILEX2.25 EUR-20.2%
  • MOLOGEN7.38 EUR-16.3%
  • THERAMETRICS0.08 CHF-11.1%

TOP

  • SANTHERA98.35 CHF4310.3%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.55 EUR-67.3%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 29.08.2014


Current issue

All issues

Product of the week

Products